Determination of clopidogrel main metabolite in plasma: A useful tool for monitoring therapy?

Therapeutic Drug Monitoring

Volumn 30, Issue 1, 2008, Pages 84-89

  Mani, Helen ^a   Toennes, Stefan W ^a   Linnemann, Birgit ^a   Urbanek, Dorota A ^a   Schwonberg, Jan ^a   Kauert, Gerold F ^a   Lindhoff Last, Edelgard ^a  

^a UNIVERSITY HOSPITAL FRANKFURT   (Germany)

Author keywords

Clopidogrel; Compliance; Therapeutic drug monitoring

Indexed keywords

ACETYLSALICYLIC ACID; ADENOSINE DIPHOSPHATE; CLOPIDOGREL; CLOPIDOGREL CARBOXYLIC ACID; DRUG METABOLITE; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BLOOD SAMPLING; CONTROLLED STUDY; DEMOGRAPHY; DRUG BLOOD LEVEL; DRUG DETERMINATION; DRUG METABOLISM; DRUG MONITORING; DRUG RESPONSE; DRUG SCREENING; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; MAJOR CLINICAL STUDY; MALE; PATIENT COMPLIANCE; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PRIORITY JOURNAL; THROMBOCYTE AGGREGATION; THROMBOCYTE AGGREGATION INHIBITION; THROMBOCYTE FUNCTION;

AGED; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; FEMALE; HUMANS; MALE; MASS SPECTROMETRY; PERIPHERAL VASCULAR DISEASES; PLATELET AGGREGATION INHIBITORS; TICLOPIDINE;

EID: 38549135088     PISSN: 01634356     EISSN: None     Source Type: Journal    
DOI: 10.1097/FTD.0b013e31815c13fd     Document Type: Article

References (18)

1. van der Wal MH, Jaarsma T, van Veldhuisen DJ. Non-compliance in patients with heart failure; how can we manage it ? Eur J Heart Fail. 2005;7:5-17.
2. Cline CM, Bjorck-Linne AK, Israelsson BY, et al. Non-compliance and knowledge of prescribed medication in elderly patients with heart failure. Eur J Heart Fail. 1999;2:145-149.
3. Schwartz KA, Schwartz DE, Ghosheh K, et al. Compliance as a critical consideration in patients who appear to be resistant to aspirin after healing of myocardial infarction. Am J Cardiol. 2005;95:973-975.
4. Cotter G, Shemesh E, Zehavi M, et al. Lack of aspirin effect: aspirin resistance or resistance to taking aspirin? Am Heart J. 2004;147:293-300.
5. Clarke TA, Waskell LA. The metabolism of clopidogrel is catalyzed by human cytochrome P450 3A and is inhibited by atorvastatin. Drug Metab Dispos. 2003;31:53-59.
6. Turpeinen M, Tolonen A, Uusitalo J, et al. Effect of clopidogrel and ticlopidine on cytochrome P450 2B6 activity as measured by bupropion hydroxylation. Clin Pharmacol Ther. 2005;77:553-559.
7. Pereillo JM, Maftouh M, Andrieu A, et al. Structure and stereochemistry of the active metabolite of clopidogrel. Drug Metab Dispos. 2002;30:1288-1295.
8. Mani H, Linnemann B, Luxembourg B, et al. Response to Aspirin and Clopidogrel monitored with different platelet function methods. Platelets. 2006;17:303-310.
9. Toennes SW, Kauert GF. Importance of Vacutainer selection in forensic toxicological analysis of drugs of abuse. J Anal Toxicol. 2001;25:339-343.
10. Mitakos A, Panderi I. Determination of the carboxylic acid metabolite of clopidogrel in human plasma by liquid chromatography-electrospray ionization mass spectrometry. Anal Chim Acta. 2004;505:107-114.
11. Lainesse A, Ozalp Y, Wong H, et al. Bioequivalence study of clopidogrel bisulfate film-coated tablets. Arzneimittelforschung. 2004;54:600-604.
12. McEwen J, Strauch G, Perles P, et al. Clopidogrel bioavailability: absence of influence of food or antacids. Semin Thromb Hemost. 1999;25(Suppl 2):47-50.
13. Tantry US, Bliden KP, Gurbel PA. Resistance to antiplatelet drugs: current status and future research. Expert Opin Pharmacother. 2005;6:2027-2045.
14. Gurbel PA, Tantry US. Drug insight: Clopidogrel nonresponsiveness. Nat Clin Pract Cardiovasc Med. 2006;3:387-395.
15. Chen WH. Antiplatelet resistance with aspirin and clopidogrel: is it real and does it matter? Curr Cardiol Rep. 2006;8:301-306.
16. Mueller MR, Salat A, Stangl P, et al. Variable platelet response to lowdose ASA and the risk of limb deterioration in patients submitted to peripheral arterial angioplasty. Thromb Haemost. 1997;78:1003-1007.
17. von Beckerath N, Kastrati A, Wieczorek A, et al. A double-blind, randomized study on platelet aggregation in patients treated with a daily dose of 150 or 75 mg of clopidogrel for 30 days. Eur Heart J. 2007;28:1814-1819.
18. Angiolillo DJ, Fernandez-Ortiz A, Bernardo E, et al. Variability in individual responsiveness to clopidogrel. J Am Coll Cardiol. 2007;49:1505-1516.